Salmonella Arthritis

  • Gabriel J. Tobón
  • Juan Esteban Garcia-Robledo
  • Ivana Nieto-Aristizábal


Salmonella spp. are gram-negative bacilli with a set of virulence factors that allow them to develop gastrointestinal tract involvement, manifested as severe diarrhoea and enteric fever syndrome, as well as extra-intestinal involvement. They have been associated with different infectious and non-infectious diseases. Since the early nineteenth century, typhoid fever has been a topic of debate. Clinical manifestations of Salmonella infections depend on the serovar involved; although most patients exhibit typical enteric fever syndrome or gastroenteritis, up to 2% develop Salmonella arthritis, which can manifest as reactive arthritis (ReA) or septic arthritis (SA).

ReA refers to immune-mediated joint damage with aseptic synovitis, usually with polyarticular involvement, whereas SA refers to the direct involvement of joint tissues by Salmonella bacilli, usually following haematogenous spread from a gastrointestinal focus and with a monoarticular compromise. Although it is infrequent, Salmonella arthritis is responsible for an important proportion of mortality and permanent disability. Therefore, awareness regarding these conditions must be raised among clinicians and researchers to improve their prevention, early diagnosis and adequate treatment.


Salmonella spp. Typhoid fever Reactive arthritis Septic arthritis Reiter’s syndrome HLA-B27 Eberth’s bacillus Interleukin-17 Lipopolysaccharide Joint involvement 



Disease-modifying antirheumatic drugs


Enteric fever syndrome




Non-steroidal anti-inflammatory drugs


Rheumatoid arthritis


Reactive arthritis


Septic arthritis


Salmonella-containing vacuole


Salmonella pathogenicity island 1



The authors declare no conflicts of interest.

There is no financial support.


  1. 1.
    Akgul O, Ozgocmen S. Classification criteria for spondyloarthropathies. World J Orthop. 2011;2(12):107.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Merola JF, Bermas B, Lu B, Karlson EW, Massarotti E, Schur PH, et al. Clinical manifestations and survival among adults with (SLE) according to age at diagnosis. Lupus. 2014;23(8):778–84.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Goldenberg DL. Septic arthritis. Lancet. 1998;351(9097):197–202.CrossRefGoogle Scholar
  4. 4.
    Singh AK, Aggarwal A, Chaurasia S, Misra R. Identification of immunogenic HLA-B∗27:05 binding peptides of Salmonella outer membrane protein in patients with reactive arthritis and undifferentiated spondyloarthropathy. J Rheumatol. 2013;40(2):173–85.PubMedCrossRefGoogle Scholar
  5. 5.
    Tuompo R, Hannu T, Mattila L, Siitonen A, Leirisalo-Repo M. Reactive arthritis following Salmonella infection: a population-based study. Scand J Rheumatol. 2013;42(3):196–202.PubMedCrossRefGoogle Scholar
  6. 6.
    Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ, Minh HC, et al. Typhoid fever. N Engl J Med. 2002;347(22):1770–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Ledermann W. Una historia del bacilo de Eberth desde Junker hasta Germanier. Rev Chil infectología. 2003;20:58–61. SpanishGoogle Scholar
  8. 8.
    Eberth CJ. Die Organismen in den Organen bei Typhus abdominalis. Arch für Pathol Anat und Physiol und für Klin Med. 1880;81(1):58–74. GermanGoogle Scholar
  9. 9.
    Vartiainen J, Hurri L. Arthritis due to Salmonella Typhimurium. Acta Med Scand. 1964;175:771–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Morgan M, Forbes KJ, Gillespie S. Salmonella septic arthritis: a case report and review. J Infect. 1990;21:195–203.PubMedCrossRefGoogle Scholar
  11. 11.
    David JR, Black RL. Salmonella arthritis. Medicine (Baltimore). 1960;39:385–403.CrossRefGoogle Scholar
  12. 12.
    Cohen JI, Bartlett JA, Corey GR. Extra-intestinal manifestations of salmonella infections. Medicine (Baltimore). 1987;66(5):349–88.CrossRefGoogle Scholar
  13. 13.
    Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of Campylobacter, Salmonella and Shigella-associated reactive arthritis. J Health Popul Nutr. 2013;31(3):299–307.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Kaandorp CJ, Dinant HJ, van de Laar MA, Moens HJ, Prins AP, Dijkmans BA. Incidence and sources of native and prosthetic joint infection : a community based prospective survey. Ann Rheum Dis. 1997;56(8):470–5.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Meijers KAE, Dijkmans BAC, Hermans J, van den Broek PJ, Cats A. Non-gonococcal infectious arthritis: a retrospective study. J Infect. 1987;14(1):13–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Gardner GC, Weisman MH. Pyarthrosis in patients with rheumatoid arthritis : a report of 13 cases and a review of the literature from the past 40 years. Am J Med. 1990;88(5):503–11.PubMedCrossRefGoogle Scholar
  17. 17.
    Cook PP, Siraj DS. Infección y artritis. 10th ed. Kelley y Firestein. Tratado de reumatología. Elsevier Espa8#241;a, S.L.U.; 2018. p. 1876–90.Google Scholar
  18. 18.
    Gelman MI, Ward JR. Septic arthritis: a complication of rheumatoid arthritis. Radiology. 1977;122(1):17–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Dubost JJ, Soubrier M, De Champs C, Ristori JM, Bussière JL, Sauvezie B. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis. 2002;61(3):267–9.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Maki-Ikola O, Leirisalo-Repo M, Kantele A, Toivanen P, Granfors K. Salmonella-specific antibodies in reactive arthritis. J Infect Dis. 1991;164(6):1141–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Noto Llana M, Sarnacki SH, Vázquez MV, Gartner AS, Giacomodonato MN, Cerquetti MC. Salmonella enterica induces joint inflammation and expression of Interleukin-17 in draining lymph nodes early after onset of enterocolitis in mice. Infect Immun. 2012;80(6):2231–9.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Atkins BL, Bowler ICJW. The diagnosis of large joint sepsis. J Hosp Infect. 1998;40:263–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Jacques P, Elewaut D, Mielants H. Interactions between gut inflammation and arthritis/spondylitis. Curr Opin Rheumatol. 2010;22(4):368–74.PubMedCrossRefGoogle Scholar
  24. 24.
    Giannella RA. Salmonella [Internet]. Medical microbiology. University of Texas Medical Branch at Galveston; 1996.Google Scholar
  25. 25.
    Su LH, Chiu CH. Salmonella: clinical importance and evolution of nomenclature. Chang Gung Med J. 2007;30(3):210–9.PubMedGoogle Scholar
  26. 26.
    Gal-Mor O, Boyle EC, Grassl GA. Same species, different diseases: how and why typhoidal and non-typhoidal Salmonella enterica serovars differ. Front Microbiol. 2014;5:391.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Fàbrega A, Vila J. Salmonella enterica serovar Typhimurium skills to succeed in the host: virulence and regulation. Clin Microbiol Rev. 2013;26(2):308–41.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Jantsch J, Chikkaballi D, Hensel M. Cellular aspects of immunity to intracellular Salmonella enterica. Immunol Rev. 2011;240(1):185–95.PubMedCrossRefGoogle Scholar
  29. 29.
    Ryan MP, O’Dwyer J, Adley CC. Evaluation of the complex nomenclature of the clinically and veterinary significant pathogen salmonella [Internet]. Vol. 2017.BioMed Research International. Hindawi Limited; 2017. p. 3782182.Google Scholar
  30. 30.
    Ochman H, Groisman EA. The evolution of invasion by enteric bacteria. Can J Microbiol. 1995;41(7):555–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Darwin KH, Miller VL. Molecular basis of the interaction of Salmonella with the intestinal mucosa. Clin Microbiol Rev. 1999;12(3):405–28.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Wallis TS, Galyov EE. Molecular basis of Salmonella-induced enteritis. Mol Microbiol. 2000;36(5):997–1005.PubMedCrossRefGoogle Scholar
  33. 33.
    Hensel M. Evolution of pathogenicity islands of Salmonella enterica. Int J Med Microbiol. 2004;294(2–3):95–102.PubMedCrossRefGoogle Scholar
  34. 34.
    Hansen-Wester I, Hensel M. Salmonella pathogenicity islands encoding type III secretion systems. Microbes Infect. 2001;3(7):549–59.PubMedCrossRefGoogle Scholar
  35. 35.
    Eichelberg K, Galán JE. Differential regulation of Salmonella typhimurium type III secreted proteins by pathogenicity island 1 (SPI-1)-encoded transcriptional activators InvF and HilA. Infect Immun. 1999;67(8):4099–105.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Rakeman JL, Bonifield HR, Miller SI. A hila-independent pathway to Salmonella typhimurium invasion gene transcription. J Bacteriol. 1999;181(10):3096–104.PubMedPubMedCentralGoogle Scholar
  37. 37.
    Foster JW. Low pH adaptation and the acid tolerance response of Salmonella typhimurium. Crit Rev Microbiol. 1995;21(4):215–37.PubMedCrossRefGoogle Scholar
  38. 38.
    Que JU, Casey SW, Hentges DJ. Factors responsible for increased susceptibility of mice to intestinal colonization after treatment with streptomycin. Infect Immun. 1986;53(1):116–23.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, et al. Intestinal inflammation allows Salmonella to use ethanolamine to compete with the microbiota. Proc Natl Acad Sci U S A. 2011;108(42):17480–5.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Selsted ME, Miller SI, Henschen AH, Ouellette AJ. Enteric defensins: antibiotic peptide components of intestinal host defense. J Cell Biol. 1992;118(4):929–36.PubMedCrossRefGoogle Scholar
  41. 41.
    Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun. 1992;60(5):1786–92.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Ledeboer NA, Frye JG, McClelland M, Jones BD. Salmonella enterica Serovar Typhimurium requires the Lpf, Pef, and Tafi Fimbriae for biofilm formation on HEp-2 tissue culture cells and chicken intestinal epithelium. Infect Immun. 2006;74(6):3156–69.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Weening EH, Barker JD, Laarakker MC, Humphries AD, Tsolis RM, Bäumler AJ. The Salmonella enterica serotype Typhimurium lpf, bcf, stb, stc, std, and sth fimbrial operons are required for intestinal persistence in mice. Infect Immun. 2005;73(6):3358–66.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Kohbata S, Yokoyama H, Yabuuchi E. Cytopathogenic effect of Salmonella typhi GIFU 10007 on M cells of murine ileal Peyer’s patches in ligated ileal loops: an ultrastructural study. Microbiol Immunol. 1986;30(12):1225–37.PubMedCrossRefGoogle Scholar
  45. 45.
    Hughes EA, Galán JE. Immune response to Salmonella: location, location, location? Immunity. 2002;16(3):325–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Pace J, Hayman MJ, Galán JE. Signal transduction and invasion of epithelial cells by S. typhimurium. Cell. 1993;72(4):505–14.PubMedCrossRefGoogle Scholar
  47. 47.
    Steele-Mortimer O. The Salmonella-containing vacuole: moving with the times. Curr Opin Microbiol. 2008;11(1):38–45.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Kingsley RA, Humphries AD, Weening EH, De Zoete MR, Winter S, Papaconstantinopoulou A, et al. Molecular and phenotypic analysis of the CS54 island of Salmonella enterica serotype Typhimurium: identification of intestinal colonization and persistence determinants. Infect Immun. 2003;71(2):629–40.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Carter JD, Hudson AP. Reactive arthritis: clinical aspects and medical management. Rheum Dis Clin N Am. 2009;35(1):21–44.CrossRefGoogle Scholar
  50. 50.
    Hannu T. Reactive arthritis. Best Pract Res Clin Rheumatol. 2011;25(3):347–57.PubMedCrossRefGoogle Scholar
  51. 51.
    Rich E, Hook EW, Alarcon GS, Moreland LW. Reactive arthritis in patients attending an urban sexually transmitted diseases clinic. Arthritis Rheum. 1996;39(7):1172–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med. 1989;320(4):216–21.PubMedCrossRefGoogle Scholar
  53. 53.
    Granfors K, Jalkanen S, Mäki-Ikola O, Lahesmaa-Rantala R, Saario R, Toivanen A, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet. 1990;335(8691):685–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Zhang Y, Gripenberg-Lerche C, Soderstrom KO, Toivanen A, Toivanen P. Antibiotic prophylaxis and treatment of reactive arthritis. Lessons from an animal model. Arthritis Rheum. 1996;39(7):1238–43.PubMedCrossRefGoogle Scholar
  55. 55.
    Granfors K, Merilahti-Palo R, Luukkainen R, Möttönen T, Lahesmaa R, Probst P, et al. Persistence of Yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis Rheum. 1998;41(5):855–62.PubMedCrossRefGoogle Scholar
  56. 56.
    Gracey E, Inman RD. Chlamydia-induced ReA: immune imbalances and persistent pathogens. Nat Rev Rheumatol. 2012;8(1):55–9.CrossRefGoogle Scholar
  57. 57.
    Anttonen K, Orpana A, Leirisalo-Repo M, Repo H. Aberrant TNF secretion by whole blood in healthy subjects with a history of reactive arthritis: time course in adherent and non-adherent cultures. Ann Rheum Dis. 2006;65(3):372–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Braun J, Yin Z, Spiller I, Siegert S, Rudwaleit M, Liu L, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum. 1999;42(10):2039–44.CrossRefGoogle Scholar
  59. 59.
    Yin Z, Braun J, Neure L, Wu P, Liu L, Eggens U, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum. 1997;40(10):1788–97.PubMedCrossRefGoogle Scholar
  60. 60.
    Appel H, Neure L, Kuhne M, Braun J, Rudwaleit M, Sieper J. An elevated level of IL-10- and TGF β-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis. Clin Rheumatol. 2004;23(5):435–40.PubMedCrossRefGoogle Scholar
  61. 61.
    Singh AK, Misra R, Aggarwal A. Th-17 associated cytokines in patients with reactive arthritis/ undifferentiated spondyloarthropathy. Clin Rheumatol. 2011;30(6):771–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol. 2007;34(11):2285–90.PubMedGoogle Scholar
  63. 63.
    Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of T helper 17 cells in peripheral blood and synovial fluid of patients with reactive arthritis. J Rheumatol. 2010;37(10):2096–9.PubMedCrossRefGoogle Scholar
  64. 64.
    Bas S, Neff L, Viatte S, Vuillet M, Spenato U, Guerne PA, et al. Relationship between gamma-interferon and interleukin-17 in Chlamydia trachomatis reactive arthritis. Clin Exp Rheumatol. 2009;27(5):885–6.PubMedGoogle Scholar
  65. 65.
    Eliçabe RJ, Di Genaro MS. Immunopathogenesis of reactive arthritis: role of the cytokines. World J Immunol. 2014;4(2):78.CrossRefGoogle Scholar
  66. 66.
    Goldenberg DL. Septic arthritis and other infections of rheumatologic significance. Rheum Dis Clin N Am. 1991;17(1):149–56.Google Scholar
  67. 67.
    Goldenberg DL, Reed JI. Bacterial arthritis. N Engl J Med. 1985;312(12):764–71.PubMedCrossRefGoogle Scholar
  68. 68.
    Morgan DS, Fisher D, Merianos A, Currie BJ. An 18 year clinical review of septic arthritis from tropical Australia. Epidemiol Infect. 1996;117(3):423–8.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Koch B, Lemmermeier P, Gause A, v Wilmowsky H, Heisel J, Pfreundschuh M. Demonstration of interleukin-1beta and interleukin-6 in cells of synovial fluids by flow cytometry. Eur J Med Res. 1996;1(5):244–8.PubMedGoogle Scholar
  70. 70.
    Verdrengh M, Tarkowski A. Granulocyte-macrophage colony-stimulating factor in Staphylococcus aureus-induced arthritis. Infect Immun. 1998;66(2):853–5.PubMedPubMedCentralGoogle Scholar
  71. 71.
    Osiri M, Ruxrungtham K, Nookhai S, Ohmoto Y, Deesomchok U. IL-1beta, IL-6 and TNF-alpha in synovial fluid of patients with non-gonococcal septic arthritis. Asian Pac J Allergy Immunol. 1998;16(4):155–60.PubMedGoogle Scholar
  72. 72.
    Abdelnour A, Bremell T, Holmdahl R, Tarkowski A. Role of T lymphocytes in experimental Staphylococcus aureus arthritis. Scand J Immunol. 1994;39(4):403–8.PubMedCrossRefGoogle Scholar
  73. 73.
    Roy S, Bhawan J. Ultrastructure of articular cartilage in pyogenic arthritis. Arch Pathol. 1975;99(1):44–7.PubMedGoogle Scholar
  74. 74.
    Dineen PF, Harty JA, Dolan AM. Septic arthritis of the ankle due to Salmonella enteritidis. Foot Ankle Surg. 2011;17(2):e23–4.PubMedCrossRefGoogle Scholar
  75. 75.
    Gupta MN, Sturrock RD, Field M. A prospective 2-year study of 75 patients with adult-onset septic arthritis. Rheumatology. 2001;40(1):24–30.PubMedCrossRefGoogle Scholar
  76. 76.
    Meyer A, Chatelus E, Wendling D, Berthelot J-M, Dernis E, Houvenagel E, et al. Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis. Arthritis Rheum. 2011;63(5):1274–80.CrossRefGoogle Scholar
  77. 77.
    Bassetti M, Nicco E, Delfino E, Viscoli C. Disseminated Salmonella paratyphi infection in a rheumatoid arthritis patient treated with infliximab. Clin Microbiol Infect. 2010;16:84–5.PubMedCrossRefGoogle Scholar
  78. 78.
    Pham OH, McSorley SJ. Protective host immune responses to Salmonella infection. Future Microbiol. 2015;10(1):101–10.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Pocock JM, Khun PA, Moore CE, Vuthy S, Stoesser N, Parry CM. Septic arthritis of the hip in a Cambodian child caused by multidrug-resistant Salmonella enterica serovar Typhi with intermediate susceptibility to ciprofloxacin treated with ceftriaxone and azithromycin. Paediatr Int Child Health. 2014;34(3):227–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Goldenberg DL. Infectious arthritis complicating rheumatoid arthritis and other chronic rheumatic disorders. Arthritis Rheum. 1989;32(4):496–502.PubMedCrossRefGoogle Scholar
  81. 81.
    Warren CP. Arthritis associated with Salmonella infections. Ann Rheum Dis. 1970;29(5):483–7.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Anand AJ, Glatt AE. Salmonella osteomyelitis and arthritis in sickle cell disease. Semin Arthritis Rheum. 1994;24(3):211–21.PubMedCrossRefGoogle Scholar
  83. 83.
    Munigangaiah S, Khan H, Fleming P, Dolan MA. Septic arthritis of the adult ankle joint secondary to Salmonella enteritidis: acase report. J Foot Ankle Surg. 2011;50(5):593–4.PubMedCrossRefGoogle Scholar
  84. 84.
    Hügle T, Schuetz P, Mueller B, Laifer G, Tyndall A, Regenass S, et al. Serum procalcitonin for discrimination between septic and non-septic arthritis. N Engl J Med. 2008;26(3):453–6.Google Scholar
  85. 85.
    Martínez-morillo M, Soria LM, Frutos AR, Segura BT, Holgado S, Olivé A. Artritis séptica de la articulación acromioclavicular : una localización atípica. 2014;10(1):37–42.Google Scholar
  86. 86.
    Barber CE, Kim J, Inman RD, Esdaile JM, James MT. Antibiotics for treatment of reactive arthritis: a systematic review and metaanalysis. J Rheumatol. 2013;40(6):916–28.PubMedCrossRefGoogle Scholar
  87. 87.
    Leirisalo-Repo M. Reactive arthritis. Scand J Rheumatol. 2005;34(4):251–9.PubMedCrossRefGoogle Scholar
  88. 88.
    Kvien TK, Gaston JSH, Bardin T, Butrimiene I, Dijkmans BAC, Leirisalo-Repo M, et al. Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis. 2004;63(9):1113–9.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Lauhio A, Leirisalo-Repo M, Lähdevirta J, Saikku P, Repo H. Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum. 1991;34(1):6–14.CrossRefGoogle Scholar
  90. 90.
    Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, Möttönen T, Hakola M, Korpela M, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheum Dis. 2000;59(7):565–70.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Ann Rheum Dis. 2003;62(7):655–8.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Rudwaleit M, Braun J, Sieper J. Treatment of reactive arthritis: a practical guide. BioDrugs. 2000;13(1):21–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Barth WF, Segal K. Reactive arthritis (Reiter’s syndrome). Am Fam Physician. 1999;60(2):499–503, 507Google Scholar
  94. 94.
    Flores D, Marquez J, Garza M, Espinoza LR. Reactive arthritis: newer developments. Rheum Dis Clin N Am. 2003;29(1):37–59, viCrossRefGoogle Scholar
  95. 95.
    Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39(12):2021–7.CrossRefGoogle Scholar
  96. 96.
    Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Rheum. 2005;53(4):613–7.CrossRefGoogle Scholar
  97. 97.
    Coakley G, Mathews C, Field M, Jones A, Kingsley G, Walker D, et al. BSR & BHPR, BOA, RCGP and BSAC guidelines for management of the hot swollen joint in adults. Rheumatology. 2006;45(8):1039–41.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Mathews CJ, Kingsley G, Field M, Jones A, Weston VC, Phillips M, et al. Management of septic arthritis: a systematic review. Ann Rheum Dis. 2007;66(4):440–5.PubMedPubMedCentralGoogle Scholar
  99. 99.
    Goldenberg DL, Brandt KD, Cohen AS, Cathcart ES. Treatment of septic arthritis: comparison of needle aspiration and surgery as initial modes of joint drainage. Arthritis Rheum. 1975;18(1):83–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Gabriel J. Tobón
    • 1
  • Juan Esteban Garcia-Robledo
    • 2
  • Ivana Nieto-Aristizábal
    • 1
  1. 1.GIRAT (Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional), Fundación Valle del Lili, Universidad IcesiCaliColombia
  2. 2.GIRAT (Grupo de Investigación en Reumatología, Autoinmunidad y Medicina Traslacional), School of Medicine, Universidad IcesiCaliColombia

Personalised recommendations